Operator 0:10 Ladies and gentlemen, thank you for standing by and welcome to the G1 commercial update. At this time all participants are in listen only mode. After the speaker's presentation … [Read more...] about GTHX Commercial Update 12/16/21-Transcript
Time For T cells: Gritstone Bio (GRTS)
Situation Snapshot A new COVID-19 variant (Omicron) was recently identified in South Africa. On 11/26/21 the World Health Organization classified Omicron as a variant of concern (VOC). The decision … [Read more...] about Time For T cells: Gritstone Bio (GRTS)
BCRX Transcript: Jefferies London Conference 2021
Maury Raycroft (analyst) Hi everyone, my name is Maury Raycroft, and I am one of the biotech analysts at Jefferies. Thanks for joining us for our London conference. And I would like to welcome the … [Read more...] about BCRX Transcript: Jefferies London Conference 2021
GRTS Transcript-Cowen 2021
Marc Farhm All right, we will. before we really get started, we'll wait for a second here to let everybody join the session. But welcome back to the fifth annual Callen IO Summit. Hopefully the … [Read more...] about GRTS Transcript-Cowen 2021
GRTS Transcript: Stifel 2021
Ben Burnett Hello everyone. My name is Ben Burnett, biotech analyst at Stifle and I'm pleased to be joined by Andrew Allen, CEO of Gritstone Gio. He's going to give a formal presentation and if … [Read more...] about GRTS Transcript: Stifel 2021
Gritstone Bio Reports Promising Preclinical Data in NHPs; Efficacy Threshold Exceeded at Low Doses
On 11/11/21 one of our core positions Gritstone Bio (GRTS) reported highly anticipated data from its CORAL COVID-19 vaccine program in non-human primates (NHPs). After scrupulous review and comparison … [Read more...] about Gritstone Bio Reports Promising Preclinical Data in NHPs; Efficacy Threshold Exceeded at Low Doses
BCRX Q3 Results & Discussion
BCRX Q3 Performance and Discussion*For a copy of Q3 earnings transcript, click here. To be directed to BCRX full page with reports and more, click here. Robust Orladeyo Launch Continues; Blockbuster … [Read more...] about BCRX Q3 Results & Discussion
Why We Dont Like Aurinia At $3B
Introduction: In response to recent backlash over bearish remarks on popular companies, we have decided to frame our stance in concise articles, starting with Aurina Pharmaceuticals (AUPH). Here we … [Read more...] about Why We Dont Like Aurinia At $3B
Gritstone Bio (GRTS) Makes History in a Historically Hopeless Setting
As mentioned in our last report, Gritstone Bio (GRTS) initially applied its next-generation heterologous (virus/sa-mRNA) vaccine technology to fight cancer. The thesis articulated by the founding … [Read more...] about Gritstone Bio (GRTS) Makes History in a Historically Hopeless Setting
BioCryst Pharmaceuticals (BCRX) 2Q21 Earnings Highlights
This morning our baby BCRX reported stellar 2Q21 earnings beating our internal expectations as well as those set by Wall Street. Key takeaways: Orladeyo launch maintained momentum and trajectory from … [Read more...] about BioCryst Pharmaceuticals (BCRX) 2Q21 Earnings Highlights
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Portuguese
Russian
Spanish
You must be logged in to post a comment.